I take a different view.
With Imugene currently at a MC of 430M, the question is, is this fairly valued on the ASX?
This is a company that has 4 -5 in the pipeline (most at Phase 1) one at Ph 2 Hervaxx.
Just taking three other bios at random;
Bot - Botanix a pipeline of 5 products (3 at Ph1, 1 at ph2, 1 at Ph 3 and FDA approved) Market cap 600M. https://botanixpharma.com/pipeline/
Imm - Immutep = 7 in pipeline (2 at late stage beyond Ph2, most others at ph 1). 550M MC https://www.immutep.com/pipeline/clinical-pipeline.html
DMX Dimerix - 4 in pipeline couple of products in ph2 - 200M MC.
AVA. -arovella - 3 in pipeline in preclinical 150M
Maybe there are better ones to compare, however I think you would be hard pressed to find another Bio on the ASX that has mainly PH1s valued at 400M+, most would be under this market cap.
Perhaps with products at Ph 1, (one at Ph 2 - Hervaxx), 400MC is fairly valued.
- Forums
- ASX - By Stock
- IMU
- Why IMU is a multi multi bagger
IMU
imugene limited
Add to My Watchlist
1.35%
!
37.5¢

Why IMU is a multi multi bagger, page-26120
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $82.39M |
Open | High | Low | Value | Volume |
37.0¢ | 37.5¢ | 36.0¢ | $342.2K | 938.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 488 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 12566 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 64143 | 0.365 |
8 | 258148 | 0.360 |
7 | 134035 | 0.355 |
16 | 165231 | 0.350 |
6 | 198970 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 12566 | 2 |
0.380 | 21000 | 2 |
0.385 | 17121 | 3 |
0.390 | 17530 | 3 |
0.395 | 222522 | 6 |
Last trade - 16.10pm 18/07/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |